文献速递血脂与心血管预防

维生素D补充对新手他汀使用者肌肉症状的影响:随机对照试验

Statin-Associated Muscle Symptoms Among New Statin Users Randomly Assigned to Vitamin D or Placebo.
PubMed 文献 · JAMA Cardiol · 2023-01-01

该随机双盲安慰剂对照试验纳入无癌症和心血管疾病的老年人群,比较每日2000 IU维生素D3与安慰剂对启动他汀治疗后肌肉症状(SAMS)及因SAMS停药的影响。

要点

  • 维生素D补充未预防他汀相关肌肉症状(SAMS)。
  • 维生素D未减少因SAMS停用他汀的比例。
  • 疗效不受基线25-羟基维生素D水平影响。

核心结论

  • 维生素D补充不能预防SAMS或减少他汀停药,且结果在不同基线25-羟基维生素D水平间一致。

研究设计与样本

  • 随机、安慰剂对照、双盲临床试验,纳入50岁以上男性和55岁以上女性(无癌症和心血管疾病),每日胆钙化醇2000 IU或安慰剂,随访期间评估他汀处方。
  • 分析样本为随机分组后启动他汀治疗的1033例维生素D组和1050例安慰剂组参与者,平均(SD)年龄66.8(6.2)岁,49%为女性。

临床怎么用

  • 对于启动他汀治疗的患者,不应以预防SAMS为目的常规补充维生素D。

局限性

  • SAMS和停药数据基于2016年初的调查问卷,可能存在回忆偏倚。
  • 研究人群为无癌症和心血管疾病的老年人群,结论外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Statin-associated muscle symptoms (SAMS) are common and may lead to discontinuation of indicated statin therapy. Observational studies suggest that vitamin D therapy is associated with reduced statin intolerance, but no randomized studies have been reported. OBJECTIVE: To test whether vitamin D supplementation was associated with prevention of SAMS and a reduction of statin discontinuation. DESIGN, SETTING, AND PARTICIPANTS: Men 50 years or older and women 55 years or older, free of cancer and cardiovascular disease, were enrolled in a randomized, placebo-controlled, double-blind clinical trial of vitamin D supplementation. Participants who initiated statin therapy after randomization were surveyed in early 2016. The data were analyzed in early 2022. INTERVENTIONS: Daily cholecalciferol (2000 international units) or placebo with assessment of statin prescriptions during follow-up. MAIN OUTCOMES AND MEASURES: Muscle pain or discomfort lasting several days (primary outcome) and discontinuation of a statin due to SAMS (secondary outcome). RESULTS: Statins were initiated by 1033 vitamin D-assigned participants and 1050 placebo-assigned participants; mean (SD) age was 66.8 (6.2) years and 49% were women. Over 4.8 years of follow-up, SAMS were reported by 317 participants (31%) assigned vitamin D and 325 assigned placebo (31%). The adjusted odds ratio (OR) was 0.97 (95% CI, 0.80-1.18; P = .78). Statins were discontinued by 137 participants (13%) assigned to vitamin D and 133 assigned to placebo (13%) with an adjusted OR of 1.04 (95% CI, 0.80-1.35; P = .78). These results were consistent across pretreatment 25-hydroxy vitamin D levels (interaction P value = .83). Among participants with levels less than 20 ng/mL, SAMS were reported by 28 of 85 vitamin D-assigned participants (33%) and 33 of 95 placebo-assigned participants (35%). For those with levels less than 30 ng/ml, SAMS were reported by 88 of 330 vitamin-D assigned participants (27%) and 96 of 323 of placebo-assigned participants (30%). CONCLUSIONS AND RELEVANCE: Vitamin D supplementation did not prevent SAMS or reduce statin discontinuation. These results were consistent across pretreatment 25-hydroxy vitamin D levels. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01169259.

来源:JAMA Cardiol,查看原文。版权归原作者所有。

引用

  1. Hlatky MA, Gonzalez PE, Manson JE, et al. Statin-Associated Muscle Symptoms Among New Statin Users Randomly Assigned to Vitamin D or Placebo. JAMA Cardiol. 2023. PMID: 36416841. doi:10.1001/jamacardio.2022.4250

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。